Search
Myriad Genetics Inc
MYGNAdd to Watchlist
5.720USD
+0.050+0.88%
Close 11-11 16:00（ET）
547.12MMarket Cap
LossP/E TTM
Myriad Genetics Inc (MYGN) Stock Price Target & Forecast
Analyst Rating
Based on 9 analysts giving stock ratings to Myriad Genetics Inc in the past month.
Hold
0 Strong Buy
1 Buy
6 Hold
1 Sell
1 Strong Sell
Target Price
4.487USD-29.33%
MYGN Analyst Recommendation Trends
In the current month, MYGN has received 1 Buy Ratings, 6 Hold Ratings, and 1 Sell Ratings. MYGN average Analyst price target in the last month is 4.488.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
0
0
0
0
0
0
0
0
1
1
2
2
2
2
3
3
6
5
6
6
7
7
7
7
1
1
1
1
1
1
1
1
1
2
1
1
1
2
2
2
9
9
10
10
11
12
13
13
MYGN Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Stryker Corp
SYK
10
14
6
0
0
30
Dexcom Inc
DXCM
13
12
4
0
0
29
Medtronic PLC
MDT
8
11
10
0
0
29
Abbott Laboratories
ABT
11
13
4
0
0
28
Guardant Health Inc
GH
12
14
2
0
0
28
Medline Ord Shs Class A
MDLN
10
12
6
0
0
28
Zimmer Biomet Holdings Inc
ZBH
2
5
20
0
0
27
Insulet Corp
PODD
7
7
12
0
0
26
Tandem Diabetes Care Inc
TNDM
5
8
10
0
0
23
Repligen Corp
RGEN
5
12
4
0
0
21
Financial Forecasting
Based on analysts' estimates, MYGN EPS is projected to reach -0.180 in FY2026Q4, following reported EPS of -0.459 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.07
-0.06
-0.20
-0.18
-0.15
Actual
-0.36
-0.46
-0.46
--
--
Surprise
-431.91%
-687.18%
-129.37%
--
--
FAQs
What is Myriad Genetics Inc's expected revenue for the next quarter?
Myriad Genetics Inc's expected revenue is 195.00M.
What is Myriad Genetics Inc's price target?
Analysts forecast that Myriad Genetics Inc's price target is USD 5.14, with the highest forecast at USD 8.00 and the lowest forecast at USD 2.50.
How have Myriad Genetics IncMYGN's recent earnings per share performed?
The market expectation was USD -0.46, while Myriad Genetics IncMYGN's earnings per share (EPS) for the previous quarter was USD -0.46. EPS for the next quarter is expected at USD -0.18.
What is the analyst rating for Myriad Genetics Inc?
Based on the ratings of Myriad Genetics Inc's stock from 9 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.